These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5656 related articles for article (PubMed ID: 306870)

  • 21. Recall skin-test antigens and the prognosis of stage I melanoma.
    Aranha GV; McKhann CF; Simmons RL; Grage TB
    J Surg Oncol; 1979; 11(1):13-6. PubMed ID: 431077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 23. Delayed cutaneous hypersensitivity ad peripheral blood lymphocyte counts in gastrointestinal cancer.
    Gupta S; Seth SK; Udupa KN; Sen PC
    Ann Acad Med Singap; 1980 Jan; 9(1):71-6. PubMed ID: 7447383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunocompetence, immunodeficiency and prognosis in cancer.
    Hersh EM; Gutterman JU; Mavligit GM; Mountain CW; McBride CM; Brugess MA; Lurie PM; Zelen M; Takita H; Vincent RG
    Ann N Y Acad Sci; 1976; 276():386-406. PubMed ID: 800324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoprofile studies for patients with bronchogenic carcinoma. I. Correlation of pretherapy studies with survival.
    Liebler GA; Concannon JP; Magovern GJ; Dalbow MH; Hodgson SE
    J Thorac Cardiovasc Surg; 1977 Oct; 74(4):506-18. PubMed ID: 302883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 27. In vivo and in vitro observation of cellular immune parameters in squamous cell carcinoma of the oral cavity and its correlation with tumor load and prognosis.
    Das SN; Khanna NN; Khanna S
    Cancer Invest; 1986; 4(3):207-16. PubMed ID: 3719410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
    Mavligit GM; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for melanoma.
    Vaisrub S
    JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.
    Moertel CG; Ritts RE; Schutt AJ; Hahn RG
    Cancer Res; 1975 Nov; 35(11 Pt 1):3075-83. PubMed ID: 1102082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Decrease in immunoreactivity in melanoma. Analysis of DNCB tests in the literature].
    Remy W; Dorn R; Ulm K; Mayerhausen W
    Z Hautkr; 1986 Dec; 61(24):1767-77. PubMed ID: 3825218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-mediated immune competence in patients with prostatic carcinoma.
    Stefani SS; Menon M; Canning JR; Clark SS
    J Urol; 1978 Oct; 120(4):431-4. PubMed ID: 702665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multiparametric observation of immune competence in breast cancer and its correlation with tumour load and prognosis.
    Das SN; Khanna NN; Khanna S
    Ann Acad Med Singap; 1985 Apr; 14(2):374-81. PubMed ID: 3876055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo and in vitro assays of immunocompetence in bronchogenic carcinoma.
    Alsabti EA
    Oncology; 1979; 36(4):171-5. PubMed ID: 157453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunologic response in patients with melanoma of the skin].
    Mutsenietse AIa; Volrat AA; Popena BA; Bumbieris IaV; Shapovalova EA
    Vopr Onkol; 1983; 29(4):34-8. PubMed ID: 6858048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective immunological evaluation of mycosis fungoides.
    Cooperrider PA; Roenigk HH
    Arch Dermatol; 1978 Feb; 114(2):207-12. PubMed ID: 629547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 283.